Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 43-45

  Mihara, Kazuo ^a   Otani, Koichi ^a   Ishida, Masayuki ^a   Yasui, Norio ^a   Suzuki, Akihito ^a   Ohkubo, Tadashi ^a   Osanai, Takako ^b   Kaneko, Sunao ^a   Sugawara, Kazunobu ^a  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

Author keywords

Cytochrome P4502D6; Haloperidol; m Chlorophenylpiperazine; Metabolism; Trazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CYTOCHROME P450; HALOPERIDOL; TRAZODONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DEPRESSION; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; TRAZODONE;

EID: 0031425502     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00007     Document Type: Article

References (17)

1. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
2. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995;17: 333-5.
3. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-6.
4. Spina E, Martines C, Caputi AP, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991;41:467-70.
5. Nilsen OG, Dale O, Husebo B. Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. Pharmacol Toxicol 1993;72:286-9.
6. Caccia S, Fong MH, Garattini S, et al. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol 1982;34:605-6.
7. Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10:143-6.
8. Ohkubo T, Osanai T, Sugawara K, et al. High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector. J Pharm Pharmacol 1995;47:340-4.
9. van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
10. Jauch R, Kopitar Z, Prox A, Zimmer A. Pharmakokinetik und Stoffwechsel von Trazodone beim Menschen. Arzneimittel-Forschung 1976;26:2084-9.
11. Mayol RF, Cole CA, Colson KE, Kerns EH. Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat. Drug Metab Dispos Biol Fate Chem 1994; 22:171-4.
12. Otani K, Ishida M, Kaneko S, et al. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 1996;18:164-7.
13. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
14. Wietholtz H, Zysset TH, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;36:401-6.
15. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-66.
16. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994;9:131-3.
17. Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Cin Psychopharmacol 1995;10:115-7.